Global Cancer Diagnostics Patent Landscape Report 2024

Global Cancer Diagnostics Market Size

The cancer diagnostics market was valued at USD 61.50 billion in 2023. It is expected to grow at a CAGR of 13.6% during the forecast period of 2024-2032 and attain a market value of USD 194.54 billion in 2032. The market value is impacted by the increasing use of such platforms and ongoing technological advancements in this field. There has been a significant increase in number of patent applications associated with cancer diagnostics, driven by increasing global incidence of cancer requires advanced diagnostic tools for early detection and treatment planning.

Patent Landscape Report Coverage

The global cancer diagnostics patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for global cancer diagnostics include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within cancer diagnostic technologies.

Flow cytometry, a powerful technique used in cancer diagnosis to analyze the physical and chemical properties of cells or particles. Using fluorescently labeled antibodies, it can identify and quantify specific cell populations, detect abnormal cell markers, and assess cell health, which is critical for diagnosing hematologic cancers such as leukemia and lymphoma. This method provides fast, accurate and detailed information about cancer cells, which helps in effective diagnosis and treatment. Therefore, such technical innovations are impacting the patent landscape significantly.

Global Cancer Diagnostics Patent Industry Outlook

• Increased awareness of cancer and government initiatives promoting regular cancer screening are increasing the demand for diagnostic supplies and instruments.

• An ageing population and an increase in the risk of cancer worldwide increase the need for diagnostic testing and boost market growth.

• The movement towards personalized medicine requires accurate and comprehensive diagnostic tools to tailor treatment to the genetic profiles of individual patients.

What are Cancer Diagnostics?

Cancer diagnostics refers to tools, materials, and equipment used in medical laboratories and clinical settings to detect, analyze, and monitor cancer. These include a wide range of products such as reagents, analysis kits, testing equipment, imaging systems (such as MRI and CT scanners), molecular diagnostic tools (such as PCR machines) and specialty equipment (such as flow cytometers and digital pathology scanners). These consumables and instruments are essential for performing various tests, analyzes and imaging studies to diagnose cancer, determine its stage, guide treatment decisions, and monitor the effectiveness of treatment and the progression of the disease over time.

Cancer diagnostics continues to evolve, driven by the growing healthcare expenditure, especially in developing economies, and supports the adoption of advanced diagnostic technologies. Large investments in research and development activities by pharmaceutical and biotechnology companies are leading to the development of new and better diagnostic products. Cooperation between diagnostic companies and research institutes enabling the development and marketing of innovative diagnostic tools, which is a driving factor to boost market value in the forecast period.

Cancer Diagnostics Industry Growth Drivers

Increasing Technological Innovation in Cancer Diagnosis is Expected to Augment the Market Growth

Technological innovations in cancer diagnosis include advances such as next-generation sequencing (NGS), digital pathology and the integration of artificial intelligence. These innovations increase the accuracy and efficiency of cancer detection, enable personalized treatment strategies and facilitate real-time monitoring of disease progression, improving patient outcomes and fueling market growth.

For instance, In June 2022, F. Hoffmann-La Roche Ltd announced the launch of its BenchMark ULTRA PLUS System (including hardware, software and assays) which is an advanced tissue staining platform. The system enables fast and accurate test results so that doctors can make timely decisions about the patient's treatment for cancer.

Rising Demand for Personalized Medicine is Expected to Propel the Cancer Diagnostics Industry Growth

The growing demand for personalized medicine in cancer care is driving the introduction of advanced diagnostic instruments and accessories. These tools enable comprehensive genomic profiling and molecular diagnostics to help oncologists tailor treatment to individual patient characteristics, improving treatment efficacy and patient outcomes and accelerating market expansion.

Cancer Diagnostics Patent Segmentation

The report provides an in-depth analysis of the patents in this field by the following segmentation -

 
Breakup by Product

• Consumables
  • Antibodies
  • Reagents
  • Probes
  • Others

• Instrument
  • Pathology Instrument
  • Imaging Instrument
  • Others

Breakup by Technology

• Positron Emission Tomography (PET)

• Computed Tomography (CT)

• Magnetic Resonance Imaging (MRI)

• Magnetic Resonance Spectroscopy (MRS)

• Multi-Parameter Flow Cytometry

• Immunohistochemistry

• Microarray

• Next Generation Sequencing (NGS)

Cancer Diagnostics Patent Segmentation Analysis

The breakup based on technology includes positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), multi-parameter flow cytometry, immunohistochemistry, microarray and next generation sequencing (NGS). Cancer diagnostic investigations have been conducted with the chosen patent families labelled based on the technologies to which they pertain.

Positron emission tomography (PET) is an advanced imaging technique used in cancer diagnosis to visualize and evaluate the metabolic activity of tissues. PET scans contain small amounts of a radioactive tracer that accumulates in areas of high metabolic activity, such as tumors. By identifying these areas, PET scans can help diagnose cancer, determine its stage, assess response to therapy and monitor disease recurrence. This non-invasive imaging plays a vital role in oncology, providing detailed information about the biological behaviour of tumours, aiding treatment planning and improving patient care.

Detailed technological data will be provided for all specified segments classified in this report.

Cancer Diagnostics Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for cancer diagnostics patents, having around 310,000 patents. The presence of a well-established healthcare infrastructure, a robust legal framework and prominent research institutions engaged in innovations contributes to the patent landscape significantly.

Holding a substantial portion of the global population, China is another vital jurisdiction and is witnessing rapid growth in patent filings. The expanding healthcare landscape in the region contributes to the evolving research capabilities, thereby influencing a surge in patent applications. Innovations like development of novel contrast agents and imaging probes is amongst major growth factors.

Patent Profile of Key Companies

Among the players with Cancer Diagnostics patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

F. Hoffmann-La Roche Ltd

Often referred to as Roche, this multinational healthcare corporation with its headquarters located in Basel, Switzerland focuses on pharmaceuticals and diagnostics. Leading the way in cancer diagnostics, Roche provides cutting-edge methods for early and precise cancer detection, including liquid and tissue biopsies and sophisticated molecular testing. The company's broad portfolio and dedication to personalized medicine greatly improve patient outcomes and cancer treatment.

Abbott

A major global healthcare company specializing in diagnostics, medical devices, nutrition and generics. In cancer diagnosis, Abbott offers a variety of products, including molecular assays and companion diagnostics, that support personalized medicine approaches. The company's innovative technologies improve cancer detection, treatment monitoring and patient outcomes worldwide.

Other companies include GE HealthCare Technologies, Inc., Qiagen N.V., and Becton Dickinson & Company among others.

Reasons to Purchase this Report

The global cancer diagnostics patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:

• Competitive Advantage: Revealing the market leaders, potential partners and innovators helps to identify which companies have important patents in this field of cancer diagnostics. This helps stakeholders identify the key players that shape the industry and predict future market dynamics.

• Innovation Insights: The patent applications show R&D’s ongoing efforts. Their analysis reveals new innovations and technologies in cancer diagnostics. This helps stakeholders stay aware and alert of advancements and potential disruptions.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as cancer diagnostics, risks of patent infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

• Legal and Regulatory Compliance: Understanding the patent landscape is critical to ensuring compliance with patent laws and regulations. It helps stakeholders navigate license agreements, avoid infringement lawsuits, and effectively use IP assets in a global marketplace.

Key Questions Answered in the Global Cancer Diagnostics Patent Landscape Report

• Who are the key players in the cancer diagnostics patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in cancer diagnostics patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the cancer diagnostics industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in cancer diagnostics?
• What are the challenges and opportunities in the cancer diagnostics patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in cancer diagnostics?

Related Reports

Global Ovarian Cancer Diagnostics and Therapeutics Market

Global Companion Diagnostics Market

Global Diagnostic Imaging Services Market

Global Pont-Of-Care (POC) Diagnostic Market

Global In-Vitro Diagnostics Market